利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.033 秒)

    Non-Viral Vector System For The Delivery Of Nucleic Acid Into The Lung
    23.
    发明申请
    Non-Viral Vector System For The Delivery Of Nucleic Acid Into The Lung 审中-公开
    非病毒载体系统将核酸递送到肺部

    公开(公告)号：US20090298917A1

    公开(公告)日：2009-12-03

    申请号：US11920500

    申请日：2006-05-20

    申请人： Thomas Kissel ,  Elke Kleemann ,  Michael Neu ,  Tobias Gessler ,  Thomas Schmehl

    发明人： Thomas Kissel ,  Elke Kleemann ,  Michael Neu ,  Tobias Gessler ,  Thomas Schmehl

    IPC分类号： A61K31/7088 ,  C12N15/63 ,  A61P11/00 ,  A61P35/00

    CPC分类号： C08G81/00

    摘要： The present invention related to a non-viral vector system for the delivery of nucleic acids which is modified on the basis of polyethylene imine (PEI) with polyethylene glycol (PEG) and which contains a peptide sequence with PTD/CPP-functionality.This vector system is used as gene transfer system for the epithelial cells of the bronchial tubes and alveoli of the lung. The system is highly stable, protects the DNA in the pulmonary environment, has a low zeta-potential and a low aggregation tendency in a medium with a high ionic strength. Furthermore, it is characterized by a low in vitro and in vivo cytotoxicity and allows for a very high transfection efficiency. The vector system according to the present invention is used for a transfection by inhalation in local pulmonary therapy.

    摘要翻译： 本发明涉及用于递送基于聚乙烯亚胺（PEI）与聚乙二醇（PEG）并且含有具有PTD / CPP-功能的肽序列的核酸的非病毒载体系统。 该载体系统用作支气管和肺泡的上皮细胞的基因转移系统。 该系统高度稳定，保护了肺部环境中的DNA，在高离子强度的培养基中具有低ζ电位和低聚集倾向。 此外，其特征在于体外和体内细胞毒性低，并且可以获得非常高的转染效率。 根据本发明的载体系统用于通过吸入在局部肺部治疗中的转染。

    Pharmaceutical compositions
    25.
    发明授权
    Pharmaceutical compositions 失效
    药物组合物

    公开(公告)号：US5364628A

    公开(公告)日：1994-11-15

    申请号：US141832

    申请日：1993-10-22

    申请人： Thomas Kissel ,  Henriette Schrank ,  Hans-Rainer Hoffmann

    发明人： Thomas Kissel ,  Henriette Schrank ,  Hans-Rainer Hoffmann

    IPC分类号： A61K9/70 ,  A61K31/40 ,  A61F13/02

    CPC分类号： A61K9/7061 ,  A61K31/40 ,  A61K9/7084

    摘要： The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterised in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

    摘要翻译： 本发明提供了一种用于经皮全身给药活性剂的药物组合物，其特征在于活性剂是苯吲哚洛尔或甲基麦角苷。 本发明还提供了一种药物组合物，其用于药理学活性剂的经皮系统性给药，其特征在于在包含亲水性聚合物的储库中含有苯妥萘洛，替扎尼定，克立马斯酮，酮替芬或甲基麦角苷作为活性剂。 此外，用于经皮系统施用药理活性剂的药物组合物，其特征在于药理活性剂在包含含有阳离子酯基的聚丙烯酸酯聚合物的储库中。

    TRIAZINE DENDRIMERS AND METHODS OF MAKING AND USING THE SAME FOR NUCLEIC ACID TRANSPORT
    28.
    发明申请
    TRIAZINE DENDRIMERS AND METHODS OF MAKING AND USING THE SAME FOR NUCLEIC ACID TRANSPORT 审中-公开
    TRIAZINE DENDRIMERS及其制备和使用它们的核酸运输方法

    公开(公告)号：US20100093094A1

    公开(公告)日：2010-04-15

    申请号：US12549182

    申请日：2009-08-27

    申请人： Thomas Kissel ,  Olivia M. Merkel ,  Meredith Mintzer ,  Eric Simanek

    发明人： Thomas Kissel ,  Olivia M. Merkel ,  Meredith Mintzer ,  Eric Simanek

    IPC分类号： C12N15/09 ,  C07H21/04

    CPC分类号： C07D403/04 ,  A61K48/0025 ,  C08G73/024 ,  C08G73/0273 ,  C08G73/0622 ,  C08G73/0633 ,  C08G73/0644 ,  C08G83/003 ,  C08L79/02 ,  C08L79/04 ,  C12N15/88

    摘要： According to one embodiment, the disclosure relates to a dendrimer complex usable for transfection of a cell and including a nucleic acid to be transfected non-covalently bound to a triazine dendrimer vector. According to another embodiment, the disclosure provides a method of transfecting a cell by contacting the cell with a dendrimer complex as described above. After the contact, the dendrimer complex enters the cell. According to a third embodiment, the disclosure relates to a method of making a triazine dendrimer complex for cell transfection by covalently bonding a series of triazine monomers to a central monomer through a series of reactions to form a triazine dendrimer, then non-covalently bonding a nucleic acid to the dendrimer to form a triazine dendrimer complex operable to transfect a cell.

    摘要翻译： 根据一个实施方案，本公开涉及可用于转染细胞并包括未共价结合于三嗪树状体载体的待转染的核酸的树状聚合物复合物。 根据另一个实施方案，本公开提供了通过使细胞与如上所述的树枝状大分子复合物接触来转染细胞的方法。 接触后，树枝状大分子复合体进入细胞。 根据第三实施方案，本公开涉及通过一系列反应将一系列三嗪单体共价键合到中心单体以形成三嗪树枝状聚合物，然后非共价键合一个三嗪树枝状聚合物，制备用于细胞转染的三嗪树枝状大分子复合物的方法 核酸到树状聚合物以形成可操作以转染细胞的三嗪树枝状聚合物复合物。

    Pharmaceutical compositions
    29.
    发明申请
    Pharmaceutical compositions 审中-公开
    药物组合物

    公开(公告)号：US20070154520A1

    公开(公告)日：2007-07-05

    申请号：US10581937

    申请日：2004-12-23

    申请人： Michael Ausborn ,  Thomas Kissel

    发明人： Michael Ausborn ,  Thomas Kissel

    IPC分类号： A61L33/00 ,  A61F2/02 ,  B05D3/02

    CPC分类号： A61L31/16 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/416 ,  A61L2300/604 ,  C08L69/00

    摘要： A device implantable into a human or animal body comprising a biodegradable polymer which comprises ethylene carbonate units of the formula A —(—C(O)—O—CH2—CH2—O—)—  A having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by a non-hydrolytic mechanism.

    摘要翻译： 可植入人体或动物体内的装置，其包含可生物降解的聚合物，其包含式A的α-碳酸酯单元（“in-line-formula”=“在线式”）=（ - C ）-O-CH 2 -CH 2 -O - ） - A <βin-line-formula description =“In-line Formulas”end =“tail”？ >的碳酸亚乙酯含量为70〜100摩尔％，特性粘度为0.4〜4.0分升/克，在氯仿中在20℃下以1g / dl的浓度测定，玻璃化转变温度为5〜50℃ C.可通过受非水解机理控制的表面侵蚀降解。